Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RANEE MEHRA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1760411326
CMS profile
170140
Location
BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$917.82

20 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $917.82 20

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RANEE MEHRA

NPI 1760411326 · CMS profile ID 170140

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760411326?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RANEE MEHRA, NPI 1760411326, CMS profile ID 170140. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760411326?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RANEE MEHRA, NPI 1760411326, CMS profile ID 170140. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760411326?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RANEE MEHRA, NPI 1760411326, CMS profile ID 170140, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1760411326?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

20 matching records · $917.82 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 20 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–20 of 20.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $30.2112/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012013373 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.2012/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000690211 CMS
Novartis Pharmaceuticals Corporation $23.8311/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992949747 CMS
AstraZeneca Pharmaceuticals LP $26.4011/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014760893 CMS
SANOFI-AVENTIS U.S. LLC $20.7511/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050172407 CMS
Merck Sharp & Dohme LLC $20.2610/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048256285 CMS
Novartis Pharmaceuticals Corporation $21.7708/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992949737 CMS
Novartis Pharmaceuticals Corporation $21.3008/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992949739 CMS
Foundation Medicine, Inc. $18.6208/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058792179 CMS
Merck Sharp & Dohme LLC $15.2907/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048256287 CMS
Coherus Biosciences Inc. $26.4807/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060244929 CMS
E.R. Squibb & Sons, L.L.C. $125.0006/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015008231 CMS
Genmab U.S., Inc. $92.4606/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051347523 CMS
AVEO Pharmaceuticals, Inc. $238.1806/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049064607 CMS
Mirati Therapeutics, Inc. $111.6205/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057997417 CMS
Exelixis Inc. $25.8204/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044543137 CMS
Incyte Corporation $14.4503/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044505163 CMS
ARRAY BIOPHARMA INC $24.0703/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049673369 CMS
Merck Sharp & Dohme LLC $21.2903/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048256283 CMS
PFIZER INC. $24.8203/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049480231 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,242.50 5
PY2022 $4,211.09 5
PY2023 $917.82 20
PY2024 $2,617.99 14
PY2025 $273.81 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,124,333.75 93
PY2024 Principal investigator $813,892.28 61
PY2023 Principal investigator $633,471.41 125
PY2022 Principal investigator $830,697.81 139
PY2021 Recipient $330.00 1
PY2021 Principal investigator $979,164.73 91
PY2020 Principal investigator $622,730.93 67
PY2019 Principal investigator $214,554.45 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

125 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $5,902.41 12/31/2023 Non-covered Recipient Entity
University of Maryland
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy for Advanced Non Small Cell Lung Cancer KEYNOTE-495 KeyImPaCT No dispute reported 06/30/2026 1042498815
Principal investigator 1 Merck Sharp & Dohme LLC $36,141.17 12/31/2023 Non-covered Recipient Entity
University of Maryland
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 1042501117
Principal investigator 1 Merck Sharp & Dohme LLC $23,704.59 12/31/2023 Non-covered Recipient Entity
University of Maryland
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 1042501299
Principal investigator 1 Merck Sharp & Dohme LLC $18,252.22 12/31/2023 Non-covered Recipient Entity
University of Maryland Greenebaum Cancer Center
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 1042549597
Principal investigator 1 Merck Sharp & Dohme LLC $70,461.33 12/31/2023 Non-covered Recipient Entity
University of Maryland Greenebaum Cancer Center
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 1042549777
Principal investigator 1 Merck Sharp & Dohme LLC $53,417.60 12/31/2023 Non-covered Recipient Entity
University of Maryland School of Medicine
Phase II Study of pembrolizumab and bavituximab for recurrent,metastatic SCCN No dispute reported 06/30/2026 1042564371
Principal investigator 1 Merck Sharp & Dohme LLC $34,190.80 12/22/2023 Non-covered Recipient Entity
University of Maryland
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 1042501107
Principal investigator 1 Merck Sharp & Dohme LLC $30,981.80 12/22/2023 Non-covered Recipient Entity
University of Maryland Greenebaum Cancer Center
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 1042548973
Principal investigator 1 Novocure Inc. $4,225.00 12/15/2023 Non-covered Recipient Entity
State of Maryland
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. No dispute reported 06/30/2026 1023009549
Principal investigator 1 Incyte Corporation $1,640.00 12/13/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814647
Principal investigator 1 Incyte Corporation $456.30 12/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814635
Principal investigator 1 Incyte Corporation $25.02 12/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814689
Principal investigator 1 Incyte Corporation $42.88 12/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814701
Principal investigator 1 Incyte Corporation $20.42 12/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814713
Principal investigator 1 Incyte Corporation $28.98 12/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814727
Principal investigator 1 Incyte Corporation $39.94 12/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814739
Principal investigator 1 Incyte Corporation $50.04 12/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814751
Principal investigator 1 Incyte Corporation $199.32 12/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814763
Principal investigator 1 Incyte Corporation $25.02 12/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814775
Principal investigator 1 Incyte Corporation $25.02 12/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814787
Principal investigator 1 Incyte Corporation $25.02 12/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814799
Principal investigator 1 Incyte Corporation $20.42 12/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814811
Principal investigator 1 Incyte Corporation $25.02 12/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814823
Principal investigator 1 Merck Sharp & Dohme LLC $45,356.00 11/21/2023 Non-covered Recipient Entity
University of Maryland Medical Group
A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB AND CHEMOTHERAPY IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1042488081
Principal investigator 1 Novocure Inc. $192.40 11/02/2023 Non-covered Recipient Entity
State of Maryland
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. No dispute reported 06/30/2026 1023009541
Principal investigator 1 Incyte Corporation $24,073.76 11/01/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814623
Principal investigator 1 Eli Lilly and Company $24,750.46 10/26/2023 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1/2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING RET FUSION-POSITIVE SOLID TUMORS MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION (LIBRETTO-001) No dispute reported 06/30/2026 1038140197
Principal investigator 1 Incyte Corporation $4,000.00 10/13/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040814523
Principal investigator 1 Incyte Corporation $10,442.00 10/13/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040814541
Principal investigator 1 Incyte Corporation $3,900.00 10/13/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040814551
Principal investigator 1 Incyte Corporation $3,250.00 10/13/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1040814563
Principal investigator 1 Incyte Corporation $23.00 09/27/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814475
Principal investigator 1 Incyte Corporation $62.00 09/27/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814487
Principal investigator 1 Incyte Corporation $286.00 09/27/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814499
Principal investigator 1 Incyte Corporation $109.00 09/27/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814511
Principal investigator 1 Merck Sharp & Dohme LLC $4,845.00 08/28/2023 Non-covered Recipient Entity
University of Maryland
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy for Advanced Non Small Cell Lung Cancer KEYNOTE-495 KeyImPaCT No dispute reported 06/30/2026 1042498813
Principal investigator 1 Merck Sharp & Dohme LLC $88,692.12 08/28/2023 Non-covered Recipient Entity
University of Maryland Baltimore
Phase II Study of pembrolizumab and bavituximab for recurrent,metastatic SCCN No dispute reported 06/30/2026 1042564361
Principal investigator 1 Incyte Corporation $585.00 08/25/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814437
Principal investigator 1 Incyte Corporation $862.00 08/25/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814449
Principal investigator 1 Incyte Corporation $65.00 08/25/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814461
Principal investigator 1 Incyte Corporation $195.00 08/16/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814375
Principal investigator 1 Incyte Corporation $2,535.00 08/16/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814389
Principal investigator 1 Incyte Corporation $585.00 08/16/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814401
Principal investigator 1 Incyte Corporation $130.00 08/16/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814413
Principal investigator 1 Incyte Corporation $1,724.00 08/16/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814425
Principal investigator 1 Merck Sharp & Dohme LLC $45,356.00 08/03/2023 Non-covered Recipient Entity
University of Maryland Medical Group
A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1042488061
Principal investigator 1 Incyte Corporation $2,967.00 07/12/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814363
Principal investigator 1 PFIZER INC. $3,412.50 07/08/2023 Non-covered Recipient Entity
University of Maryland Baltimore
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF SASANLIMAB COMBINED WITH ANTICANCER THERAPIES TARGETING MULTIPLE MOLECULAR MECHANISMS IN PARTICIPANTS WITH NONSMALL CELL LUNG CANCER NSCLC No dispute reported 06/30/2026 1046490009
Principal investigator 1 Incyte Corporation $1,629.90 06/23/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814025
Principal investigator 1 PFIZER INC. $5,040.00 05/26/2023 Non-covered Recipient Entity
University of Maryland Baltimore
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF SASANLIMAB COMBINED WITH ANTICANCER THERAPIES TARGETING MULTIPLE MOLECULAR MECHANISMS IN PARTICIPANTS WITH NONSMALL CELL LUNG CANCER NSCLC No dispute reported 06/30/2026 1046520823
Principal investigator 1 Novocure Inc. $1,592.50 05/25/2023 Non-covered Recipient Entity
State of Maryland
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. No dispute reported 06/30/2026 1023009515
Principal investigator 1 AstraZeneca UK Limited $7,687.50 05/22/2023 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
An Open-Label Multi-Center Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or who Previously Received Durvalumab in Other Protocols WAVE No dispute reported 06/30/2026 991129149
Principal investigator 1 Incyte Corporation $28.98 05/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814265
Principal investigator 1 Incyte Corporation $39.94 05/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814277
Principal investigator 1 Incyte Corporation $199.32 05/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814291
Principal investigator 1 Incyte Corporation $2,138.40 05/05/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814013
Principal investigator 1 Incyte Corporation $35.08 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814039
Principal investigator 1 Incyte Corporation $19.38 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814051
Principal investigator 1 Incyte Corporation $20.26 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814063
Principal investigator 1 Incyte Corporation $42.00 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814077
Principal investigator 1 Incyte Corporation $74.13 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814089
Principal investigator 1 Incyte Corporation $40.76 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814101
Principal investigator 1 Incyte Corporation $0.32 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814113
Principal investigator 1 Incyte Corporation $42.88 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814127
Principal investigator 1 Incyte Corporation $0.90 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814139
Principal investigator 1 Incyte Corporation $20.42 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814151
Principal investigator 1 Incyte Corporation $25.02 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814165
Principal investigator 1 Incyte Corporation $44.64 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814177
Principal investigator 1 Incyte Corporation $4.00 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814191
Principal investigator 1 Incyte Corporation $2.08 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814203
Principal investigator 1 Incyte Corporation $50.04 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814217
Principal investigator 1 Incyte Corporation $7.10 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814227
Principal investigator 1 Incyte Corporation $10.20 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814241
Principal investigator 1 Incyte Corporation $4.65 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814253
Principal investigator 1 Incyte Corporation $25.02 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814303
Principal investigator 1 Incyte Corporation $25.02 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814315
Principal investigator 1 Incyte Corporation $20.42 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814327
Principal investigator 1 Incyte Corporation $25.02 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1040814339
Principal investigator 1 Incyte Corporation $25.02 04/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814351
Principal investigator 1 Incyte Corporation $13,075.20 04/07/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040814001
Principal investigator 1 Blueprint Medicines Corporation $4,828.00 03/23/2023 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC No dispute reported 06/30/2026 1051254089
Principal investigator 1 Blueprint Medicines Corporation $29,333.00 03/23/2023 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC No dispute reported 06/30/2026 1051254095
Principal investigator 1 Incyte Corporation $4,158.00 03/15/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813523
Principal investigator 1 Incyte Corporation $25.02 03/08/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813559
Principal investigator 1 Novocure Inc. $192.40 02/23/2023 Non-covered Recipient Entity
State of Maryland
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. No dispute reported 06/30/2026 1023009503
Principal investigator 1 Incyte Corporation $4,158.00 02/03/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813485
Principal investigator 1 Novocure Inc. $3,347.50 02/02/2023 Non-covered Recipient Entity
State of Maryland
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. No dispute reported 06/30/2026 1023009483
Principal investigator 1 GlaxoSmithKline, LLC. $2,673.88 01/27/2023 Non-covered Recipient Entity
UNIVERSITY OF MARYLAND BALTIMORE
A PHASE 1B/2A PILOT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A No dispute reported 06/30/2026 1006159227
Principal investigator 1 Incyte Corporation $42.88 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813535
Principal investigator 1 Incyte Corporation $12.51 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813547
Principal investigator 1 Incyte Corporation $61.26 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813571
Principal investigator 1 Incyte Corporation $25.02 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813581
Principal investigator 1 Incyte Corporation $77.60 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813599
Principal investigator 1 Incyte Corporation $10.90 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813611
Principal investigator 1 Incyte Corporation $12.80 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813623
Principal investigator 1 Incyte Corporation $22.00 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813635
Principal investigator 1 Incyte Corporation $21.80 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813649
Principal investigator 1 Incyte Corporation $70.50 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813661
Principal investigator 1 Incyte Corporation $66.00 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813673
Principal investigator 1 Incyte Corporation $23.50 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813685
Principal investigator 1 Incyte Corporation $16.65 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813698
Principal investigator 1 Incyte Corporation $49.95 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813711
Principal investigator 1 Incyte Corporation $51.20 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813723
Principal investigator 1 Incyte Corporation $38.40 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813735
Principal investigator 1 Incyte Corporation $43.60 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813747
Principal investigator 1 Incyte Corporation $44.00 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813759
Principal investigator 1 Incyte Corporation $10.20 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813773
Principal investigator 1 Incyte Corporation $42.88 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813789
Principal investigator 1 Incyte Corporation $12.80 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813801
Principal investigator 1 Incyte Corporation $10.90 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813813
Principal investigator 1 Incyte Corporation $12.80 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813825
Principal investigator 1 Incyte Corporation $21.80 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813837
Principal investigator 1 Incyte Corporation $12.80 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813851
Principal investigator 1 Incyte Corporation $22.00 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813865
Principal investigator 1 Incyte Corporation $23.50 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813875
Principal investigator 1 Incyte Corporation $22.00 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813889
Principal investigator 1 Incyte Corporation $21.80 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813901
Principal investigator 1 Incyte Corporation $16.65 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813913
Principal investigator 1 Incyte Corporation $70.50 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813927
Principal investigator 1 Incyte Corporation $38.40 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813939
Principal investigator 1 Incyte Corporation $12.80 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813953
Principal investigator 1 Incyte Corporation $10.90 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813965
Principal investigator 1 Incyte Corporation $16.65 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813977
Principal investigator 1 Incyte Corporation $23.50 01/10/2023 Covered Recipient Teaching Hospital
University Of Maryland Med Sys
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1040813989
Principal investigator 1 PFIZER INC. $3,367.50 01/06/2023 Non-covered Recipient Entity
University of Maryland Baltimore
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF SASANLIMAB COMBINED WITH ANTICANCER THERAPIES TARGETING MULTIPLE MOLECULAR MECHANISMS IN PARTICIPANTS WITH NONSMALL CELL LUNG CANCER NSCLC No dispute reported 06/30/2026 1046349143